Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Featured trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

  • 290 views
  • 25 Mar, 2021
  • 1 location
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA

  • 0 views
  • 21 Jul, 2022
  • 68 locations
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic

anterior uveitis
ly3009104
eye drops
corticosteroid therapy
corticosteroids
  • 23 views
  • 10 Jul, 2022
  • 24 locations
RA-PRO PRAGMATIC TRIAL (RA-PROPR)

medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in

leflunomide
tocilizumab
baricitinib
rituximab
tumor necrosis factor
  • 0 views
  • 28 Jun, 2022
  • 1 location
BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)

Rheumatoid arthritis (RA) is a frequent and disabling disease, requiring early management to achieve clinical remission. Recently, baricitinib (jak1-jak2 inhibitor) has been shown to as an

  • 0 views
  • 24 Apr, 2022
  • 1 location
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis (CRI-RA)

patients treated with a combination of MTX and biologic as second-line therapy. Less than 10% of patients treated with a combination of MTX and another targeted DMARD, such as baricitinib, as

remission
antirheumatics
anakinra
baricitinib
rheumatism
  • 0 views
  • 15 Mar, 2022
  • 6 locations
Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).

  • 0 views
  • 22 Mar, 2022
  • 1 location
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM (MYOJAK)

This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24

dermatomyositis
polymyositis
muscle enzyme
MRI
arthritis
  • 0 views
  • 03 Jun, 2022
  • 1 location
Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Treatment of Idiopathic Inflammatory Myopathies

This study aims to explore the clinical characteristics and mechanism research of inhibitors of janus kinase in the treatment of idiopathic inflammatory myopathies

immunosuppressive agents
  • 0 views
  • 14 Jun, 2022
  • 1 location
A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to

body mass index
antirheumatics
tumor necrosis factor alpha
baricitinib
tumor necrosis factor
  • 892 views
  • 26 Jul, 2022
  • 107 locations